Non-Hormonal Options for Managing Perimenopause Symptoms

Hormone therapy is the most effective treatment for many menopause symptoms, but it's not the only option, and it's not right for everyone. Some women have contraindications such as a history of hormone-sensitive breast cancer. Others simply prefer non-hormonal approaches.

The good news is that the landscape for non-hormonal menopause treatment has expanded significantly. The challenge is separating what actually has evidence behind it from what is marketed on hope. This article focuses exclusively on interventions with meaningful clinical data.

Prescription non-hormonal medications

Fezolinetant (Veozah): a new mechanism

Fezolinetant, sold under the brand name Veozah, was approved by the FDA in May 2023 and represents the first truly new mechanism for treating hot flashes in decades. It is a neurokinin 3 (NK3) receptor antagonist, meaning it works directly on the temperature regulation center in the brain rather than on hormone pathways.

This is significant because hot flashes are not caused directly by low estrogen. They result from changes in the hypothalamic thermoregulatory center, specifically involving neurons that express kisspeptin, neurokinin B, and dynorphin (KNDy neurons). When estrogen declines, these neurons become overactive, narrowing the body's thermoneutral zone. Fezolinetant blocks the neurokinin 3 receptor, calming this overactivity.

In clinical trials, fezolinetant reduced the frequency of moderate-to-severe hot flashes by approximately 60% and also reduced their severity. The effect was evident within the first week of treatment and sustained through 52 weeks of follow-up.

Important considerations: Veozah requires liver function monitoring (blood tests before starting and periodically during treatment) due to a small risk of liver injury. It is not recommended for women with known liver disease. Cost can also be a barrier, as not all insurance plans cover it.

SSRIs and SNRIs: repurposed for hot flashes

Several antidepressant medications in the SSRI and SNRI classes have been shown to reduce hot flash frequency and severity. Paroxetine (Brisdelle) is the only SSRI with specific FDA approval for menopausal hot flashes, at a low dose of 7.5 mg daily, lower than the typical antidepressant dose.

Other SSRIs and SNRIs that have shown benefit in clinical trials include venlafaxine, desvenlafaxine, escitalopram, and citalopram. These are prescribed off-label for hot flashes. Research suggests they can reduce hot flash frequency by 25-50%, which is less effective than hormone therapy but meaningful for many women.

Other prescription options

Gabapentin and pregabalin, primarily used for nerve pain and seizures, have modest evidence for hot flash reduction. Clonidine, a blood pressure medication, has also shown some benefit but is limited by side effects including dizziness and dry mouth. Oxybutynin, an overactive bladder medication, has shown promising results in reducing hot flashes in some studies.

Cognitive behavioral therapy: stronger evidence than you might expect

CBT for vasomotor symptoms

Cognitive behavioral therapy might seem like an unlikely treatment for hot flashes, but the evidence is substantial. The MENOS trials, conducted in the UK, demonstrated that CBT significantly reduced the impact and distress of hot flashes and night sweats in both menopausal women and breast cancer survivors.

CBT for vasomotor symptoms doesn't reduce the frequency of hot flashes (you still have them). What it does is change how you perceive and respond to them. By modifying catastrophic thinking patterns ("this is unbearable"), developing coping strategies, and reducing the stress response that amplifies hot flash severity, CBT can substantially reduce the bother and interference of hot flashes in daily life.

The MENOS 2 trial found that group CBT delivered in just four 90-minute sessions produced improvements that were sustained at 26-week follow-up. This makes it one of the most cost-effective interventions available.

CBT for menopause-related insomnia (CBT-I)

Sleep disruption is one of the most common and debilitating symptoms of perimenopause. Cognitive behavioral therapy for insomnia (CBT-I) is now considered the first-line treatment for chronic insomnia by the American College of Physicians, ahead of medication.

CBT-I addresses the behavioral and cognitive factors that perpetuate insomnia: irregular sleep schedules, excessive time in bed, anxiety about sleep, and unhelpful sleep habits. Multiple studies have demonstrated its effectiveness specifically in menopausal women, with improvements in sleep onset, sleep maintenance, and sleep quality.

CBT-I is typically delivered in 4-8 sessions and can be accessed through trained therapists, structured group programs, or validated digital platforms.

Exercise: what the evidence actually shows

Exercise is frequently recommended for menopause symptom management, but the evidence is more nuanced than the broad recommendation suggests:

Strong evidence

• Mood and mental health. Regular exercise consistently shows benefits for anxiety, depression, and overall psychological well-being during the menopausal transition.
• Sleep quality. Moderate aerobic exercise improves sleep quality in menopausal women, though vigorous exercise close to bedtime may have the opposite effect.
• Metabolic health. Exercise improves insulin sensitivity, body composition, and cardiovascular risk factors during menopause.
• Bone density. Weight-bearing and resistance exercise helps maintain bone density, which becomes critical as estrogen declines.

Mixed evidence

• Hot flashes. The evidence for exercise reducing hot flash frequency is inconsistent. Some studies show benefit, others show no effect, and some suggest intense exercise may temporarily trigger hot flashes. Exercise may help more through indirect pathways (stress reduction, improved sleep, better thermoregulation) than through direct hot flash reduction.

The bottom line on exercise: it may or may not reduce your hot flashes, but it will likely improve nearly every other aspect of your health during the transition. The recommendation for 150 minutes of moderate aerobic activity plus resistance training twice per week is well-supported for overall menopausal health.

Supplements and botanicals: what has data

The supplement market for menopause is enormous and largely unregulated. Most products lack rigorous clinical evidence. Here is an honest assessment of the most commonly discussed options:

Some evidence of benefit

• Black cohosh. The most studied herbal supplement for hot flashes. Results are mixed across trials, but some studies show modest benefit. The mechanism is unclear. Quality and standardization vary significantly between products. Generally considered safe for short-term use, though rare cases of liver toxicity have been reported.
• Phytoestrogens (soy isoflavones). Research suggests a modest reduction in hot flash frequency with consistent soy isoflavone intake, though the effect size is smaller than prescription treatments. The S-equol hypothesis suggests that only women who can convert isoflavones to S-equol (roughly 30-50% of Western populations) may benefit. Results vary significantly across studies.

Limited or insufficient evidence

What doesn't work (despite the marketing)

Some interventions are widely marketed for menopause but lack evidence of benefit for vasomotor symptoms:

• Magnetic therapy. No evidence for hot flash reduction.
• Homeopathy. Systematic reviews have found no benefit beyond placebo for menopausal symptoms.
• Reflexology. While potentially relaxing, no evidence for specific menopause symptom reduction.
• Progesterone creams (over-the-counter). OTC creams contain insufficient progesterone to affect symptoms and do not provide endometrial protection for women on estrogen therapy.

Building a non-hormonal toolkit

Most women who manage menopause without hormones use a combination of approaches rather than a single intervention. An evidence-based toolkit might include:

1. Address the most bothersome symptom first. For severe hot flashes, discuss fezolinetant or an SSRI/SNRI with your provider. For sleep, start with CBT-I.
2. Add structured exercise. Even if it doesn't directly reduce hot flashes, the downstream benefits for mood, sleep, metabolism, and bone health are well-established.
3. Consider CBT for hot flash coping. Particularly valuable when used alongside other treatments, and when hot flashes cause significant distress or anxiety.
4. Be selective about supplements. If you want to try a supplement, choose one with at least some evidence (like standardized black cohosh or soy isoflavones), use a third-party tested product, and give it 8-12 weeks before evaluating.
5. Track what works for you. Individual responses vary enormously. Systematic tracking of symptoms and interventions helps identify what's actually helping versus what's coincidence.

The bottom line

Non-hormonal menopause management has more evidence-based options than ever before. Fezolinetant offers a genuinely new mechanism for hot flash treatment. CBT has stronger evidence than most women realize. Exercise and lifestyle interventions provide broad benefits even if they don't specifically eliminate hot flashes.

The key is being evidence-based in your choices, honest with yourself about what's working, and willing to combine approaches for the best outcome. And if non-hormonal options aren't providing adequate relief, that's important information too. It's worth revisiting the conversation about hormone therapy with a knowledgeable provider.